{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"2"},{"groupId":"OG006","value":"0"},{"groupId":"OG007","value":"0"},{"groupId":"OG008","value":"0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"8"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"4"},{"groupId":"OG007","value":"4"},{"groupId":"OG008","value":"3"}],"units":"Participants"}],"description":"Prostate-specific antigen decline by more than 50% from baseline was analyzed. PSA partial response was defined as a ≥50% decline in PSA from Cycle 1 Day 1 (baseline) PSA value. This PSA decline much be confirmed to be sustained by a second PSA value obtained 4 or more weeks later.","groups":[{"description":"PF-06952229 was administered at a dose of 20 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG000","title":"Part 1A: PF-06952229 20mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 40 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG001","title":"Part 1A: PF-06952229 40mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 80 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG002","title":"Part 1A: PF-06952229 80mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 150 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG003","title":"Part 1A: PF-06952229 150mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG004","title":"Part 1A: PF-06952229 250mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 375 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG005","title":"Part 1A: PF-06952229 375mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 500 mg orally BID for 7 days on, 7 days off for each Cycle (one cycle = 28 days).","id":"OG006","title":"Part 1A: PF-06952229 500mg Monotherapy"},{"description":"PF-06952229 was administered at a dose of 250 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally once a day (QD) as continuous daily dosing.","id":"OG007","title":"Part 1B: PF-06952229 250mg + Enzalutamide"},{"description":"PF-06952229 was administered at a dose of 375 mg orally twice daily (BID) for 7 days on, 7 days off for each Cycle (one cycle = 28 days) in combination with enzalutamide at 160 mg orally QD as continuous daily dosing.","id":"OG008","title":"Part 1B: PF-06952229 375mg + Enzalutamide"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Population included all enrolled participants who had metastatic castration resistant prostate cancer (mCRPC)","reportingStatus":"POSTED","timeFrame":"Baseline, Cycle 1 Day 1 (at the beginning of Cycle 1), and then every 3 cycles (each cycle is 28 days) until end of treatment (an average of 1 year)","title":"Number of Participants With Prostate Specific Antigen 50 (PSA50) Response","type":"SECONDARY","unitOfMeasure":"Participants"}